We conclude that the oligomannuronate-chromium (III) complex might provide the basis for an adjuvant therapy of type 2 diabetes by enhancing insulin sensitivity with a lower toxicity profile than that of metformin. This evidence concerns the gene INS and type 2 diabetes mellitus.